Drugstore.com earnings
This article was originally published in The Tan Sheet
Executive Summary
OTC net sales advanced 18.3 percent to $234.3 million in 2007, "in line with e-commerce trends, but below our expectations due to increased marketing costs in paid search and portals," the e-commerce marketer announces during a Feb. 6 analyst meeting. Gross profit for OTCs during the year advanced 19.8 percent to $69.8 million. For the fourth quarter, OTC revenues were up 17.4 percent to $65.8 million, while gross profit for the period advanced 31.6 percent to $20.5 million. Drugstore.com's net sales for the full year grew 7.2 percent to $445.7 million, though the firm experienced a $9 million loss during the quarter, an improvement over a loss of $13 million last year. In 2008, the company plans to fuel top-line revenue growth in part by driving OTC sales up 20 percent year-over-year, the company says...
You may also be interested in...
Rite Aid-drugstore.com OTC site
Drugstore.com will host an online Rite Aid OTC store slated to launch this year, the companies say Sept. 4. Camp Hill, Pa.-based Rite Aid will receive rights to all Rx drugs ordered online for in-store pickup and will pay drugstore.com $10 million. "Having our own online OTC store and being able to market directly" to the pharmacy chain's customer base "is an important next step in our digital strategy," says Rite Aid Chief Operating Officer Rob Easley. Dawn Lepore, CEO of Bellevue, Wash.-based drugstore.com, says she expects increased sales as "Rite Aid will develop marketing programs to drive traffic to the new site." The e-retailer's 2007 net sales, announced in February, were below expectations due to increased marketing costs (1"The Tan Sheet" Feb. 11, 2008, In Brief)
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.